ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Recommended wait time for SOT candidates with a prior history of prostate cancer

Recommended wait time for SOT candidates with a prior history of prostate cancer
Risk/stage Survival Time interval to transplant Additional considerations
Very low risk <1% risk of mets/death over 15 years None Surveillance is strongly recommended
  • PSA <10 ng/mL
      
  • 3 or fewer cores of Gleason 6 (grade group 1); no greater than 50% of individual core
     Extenuating circumstances may require treatment
  • T1c to T2a
      
Low risk ~2 to 3% risk of mets/death over 15 years None Surveillance is strongly recommended
  • PSA <10 ng/mL
      
  • Gleason 6 (not meeting very low-risk criteria)
     Extenuating circumstances may require treatment
  • T1c to T2a
      
Low-volume intermediate risk
  • One of the following criteria: PSA >10 ng/mL, Gleason 7 (grade group 2 or 3), T2b
 <5% risk of mets/death over 15 years

If surveillance, no wait time

If treatment initiated, and nomogram predicts cancer-specific death over the next 15 years <10%, no wait time 		Surveillance or treatment, depending on patient and cancer characteristics
High-volume intermediate risk, high risk, or very high risk
  • PSA >20 ng/mL or high-volume Gleason 7 or any Gleason 8 to 10, T3
 20 to 70% risk of mets/death over 15 years If treatment initiated, and nomogram predicts cancer-specific death over the next 15 years <10%, no wait time Treatment
Metastatic castration-sensitive Median survival ~5 to 6 years If stable disease for 2 years with prolonged estimated life expectancy, may consider transplant Best systemic therapy ± local treatment
Metastatic castration-resistant Median survival 2 to 3 years Not a SOT candidate Best systemic therapy
PSA: prostate specific antigen.
From: Al-Adra DP, Hammel L, Roberts, J, et al. Pretransplant solid organ malignancy and organ transplant candidacy: A consensus expert opinion statement. Am J Transplant 2021; 21:460. https://onlinelibrary.wiley.com/doi/10.1111/ajt.16318. Copyright © 2021 John Wiley & Sons Ltd. Reproduced with permission of John Wiley & Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: [email protected] or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (https://onlinelibrary.wiley.com/).
Graphic 135216 Version 1.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟